Bosutinib is an inhibitor of Src and Abl with IC50 of 1.2 nM and 1 nM.

UM-164 is a potent dual c-Src/p38 kinase inhibitor that exhibits potent anti-TNBC activity in xenograft models. UM-164 inhibits p38 kinase and binds to an inactive c-Src conformation.

Hck Blocker compound B9 is a Nef-dependent Hck blocker with IC50 value of 2.8μM for Nef-Hck complex but >20μM for Hck alone. It binds directly to Nef via a pocket formed by the Nef dimerization interface and disrupts Nef dimerization in cells.

DGY-06-116 is an irreversible covalent and selective Src inhibitor.

SI-2 hydrochloride (EPH 116 hydrochloride) is a highly promising SRC-3 SMI: SRC-3 inhibitor (PPI), with IC50 values of 3-20 nM for breast cancer cell death. SI-2 hydrochloride (EPH 116 hydrochloride) has a much improved toxicity and pharmacokinetic profile, with acceptable oral availability[1].

CH6953755 is a selective inhibitor of YES1 kinase with IC50 of 1.8 nM.

AMG-47a is a Lck inhibitor that can decrease T cell proliferation with anti-inflammatory activity.

PP2 is a ATP-competitive inhibitor of the Src family of protein tyrosine kinases. The IC50s for p56lck, p59fynT, Hck, Src are 4 nM, 5 nM, 5 nM, 100 nM, respectively.

KX1-004 is a potent small molecule inhibitor of Src-PTK as a potential protective drug for NIHL.

KX2-391 is an inhibitor of Src with IC50 of 9 nM-60 nM in cancer cells. It is the first clinical and peptidomimetic class Src inhibitor.

A-770041 is selective and orally active Src-family Lck inhibitor and is a 147 nM inhibitor of Lck(1 mM ATP) and is 300-fold selective against Fyn, the other Src family kinase involved in T-cell signaling.

WH-4-023 is an inhibitor of Lck and Src with IC50 of 2 nM, 6 nM, respectively.

RK-24466 is an inhibitor of Lck (64-509) and LckCD isoforms with IC50s of <2 nM.